Survival predictors in second-line chemotherapy for metastatic gastric cancer

被引：0
|
作者：
Bohanes, P. O. [1 ]
Courvoisier, D. [1 ]
Perneger, T. [1 ]
Morel, P. [1 ]
Huber, O. [1 ]
Roth, A. D. [1 ]
机构：
[1] Univ Hosp Geneva, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15575
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Optimal indications for second-line chemotherapy in advanced gastric cancer
    Hasegawa, Hiroko
    Fujitani, Kazumasa
    Nakazuru, Shoichi
    Hirao, Motohiro
    Mita, Eiji
    Tsujinaka, Toshimasa
    ANTI-CANCER DRUGS, 2012, 23 (04) : 465 - 470
  • [32] Prognostic impact of response to second-line chemotherapy on overall survival of patients with advanced gastric cancer
    Kim, S.
    Hwang, M.
    Park, Y.
    Park, S.
    Kim, Y.
    Ryu, K.
    Lee, J.
    Park, Y.
    Kim, N.
    Park, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Second-line chemotherapy in advanced and metastatic CRC
    Roque i Figuls, Marta
    Sola, Ivan
    Martin-Richard, Marta
    Lopez, Juan-Jose
    Bonfill Cosp, Xavier
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02):
  • [34] Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer
    Seo, Myung-Deok
    Lee, Keun-Wook
    Lim, Joo Han
    Yi, Hyeon Gyu
    Kim, Dae-Young
    Oh, Do-Youn
    Kim, Jee Hyun
    Im, Seock-Ah
    Kim, Tae-You
    Lee, Jong Seok
    Bang, Yung-Jue
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (09) : 589 - 595
  • [35] Efficacy and prognostic factor analysis in second-line chemotherapy for elderly patients with metastatic gastric cancer.
    Shoji, Ayaka
    Hasegawa, Hiroko
    Kato, Seiya
    Kiyota, Ryosuke
    Shinkai, Kazuma
    Tashiro, Taku
    Ishihara, Akio
    Iwasaki, Tetsuya
    Tanaka, Satoshi
    Akasaka, Tomofumi
    Sakakibara, Yuko
    Nakazuru, Shoichi
    Ishida, Hisashi
    Hirao, Motohiro
    Mita, Eiji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] Patterns of second-line chemotherapy for metastatic prostate cancer in the United States
    Wang, Hongwei
    Liao, Laura
    Obi-Tabot, Eliot
    Sands, Robert
    Rose, Mathieu
    Zhang, Quanwu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Second-line FOLFOX chemotherapy in patients with metastatic gallbladder cancer and cholangiocarcinoma
    Luis Leal, Jose
    Carlos Roa, Juan
    Jarufe, Nicolas
    Madrid, Jorge
    Ibanez, Carolina
    Elisa Herrera, Maria
    Garrido, Marcelo
    Nervi, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [38] Landscape and future perspectives of second-line chemotherapy for metastatic pancreatic cancer
    Imaoka, Hiroshi
    Shibuki, Taro
    Satake, Tomoyuki
    Watanabe, Kazuo
    Sasaki, Mitsuhito
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    ANNALS OF ONCOLOGY, 2023, 34 : S1363 - S1363
  • [39] Is ramucirumab still the only second-line treatment in metastatic gastric cancer?
    El Gharib, Khalil
    Kourie, Hampig Raphael
    PHARMACOGENOMICS, 2020, 21 (17) : 1203 - 1206
  • [40] Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer
    Hironaka S.
    Zenda S.
    Boku N.
    Fukutomi A.
    Yoshino T.
    Onozawa Y.
    Gastric Cancer, 2006, 9 (1) : 14 - 18
12345